Emergent sucraid oral solution
Ended Awarded Last action
- Contract number
- 36C24925F0059
- Awardee
-
QOL Medical LLC UEI M1NNLZQB9HA5
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $32,426
Award facts
- Contract value 100% obligated
- $32,425.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Vero Beach, FL, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $7,138 | |
| Original award | $25,287 |
About this award
This federal contract award was issued by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to QOL Medical LLC, a specialty biopharmaceutical company. The contract is a delivery order for SUCRAID (sacrosidase) oral solution, an enzyme replacement therapy used to treat congenital sucrase-isomaltase deficiency. The contract has a ceiling value of $32,425.76 and a period of performance through November 30, 2024.
QOL Medical LLC holds a multiple-award Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) with the VA VHA, which serves as the primary vehicle for the company to supply SUCRAID to support the VA's nationwide healthcare system for veterans. The delivery order was issued against this larger indefinite delivery vehicle (IDV) contract, which has a ceiling value of $4,512,140 and a period of performance through August 31, 2025. This contract enables various VHA integrated service networks to efficiently procure pharmaceutical products, primarily SUCRAID, through streamlined ordering processes.
The contract does not have a set-aside designation. QOL Medical LLC is the prime contractor, and there is no information provided about any major subcontractors. As a specialty biopharmaceutical company focused on rare diseases, QOL Medical's provision of this critical enzyme replacement therapy demonstrates its important role in supporting the VA's mission to provide quality healthcare to veterans.
Quick answers
Who was awarded contract 36C24925F0059?
36C24925F0059 was awarded to QOL Medical LLC by Veterans Integrated Service Network 9 (Veterans Health Administration) on October 29, 2024.
How much is contract 36C24925F0059 worth?
The government has obligated $32,426 on 36C24925F0059.
Is contract 36C24925F0059 an order under another contract?
Yes. 36C24925F0059 is a delivery order under 36F79720D0226, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24925F0059 competed?
The extent of competition for 36C24925F0059 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award